- Investor's Business Daily•yesterday
Amgen trumped Regeneron and Sanofi this week as prescriptions of its cholesterol-cutting drug grew.
A European Medicines Agency panel said on Friday it recommended granting marketing approval to Sanofi and Regeneron's experimental drug to treat rheumatoid arthritis. The Committee for Medicinal Products for Human Use gave a positive opinion on the drug, Kevzara, citing its ability to reduce the signs and symptoms of rheumatoid arthritis. Sarilumab, the active substance of Kevzara, a treatment for adult patients with moderate to severe rheumatoid arthritis, works by blocking a protein called IL-6, which is associated with inflammation.
- American City Business Journals•3 days ago
Sanofi Genzyme’s next potential blockbuster treatment is running into legal trouble in California, where a unit of Amgen has accused the Cambridge rare disease drugmaker of infringing one of its patents. Immunex Corp., a subsidiary of Amgen (AMGN), filed a complaint in Los Angeles federal court on April 5 claiming that an eczema drug developed by Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) infringes a patent related to a failed asthma treatment.
REGN: Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
|Bid||365.00 x 200|
|Ask||389.00 x 100|
|Day's range||368.86 - 379.20|
|52-week range||325.35 - 452.96|
Trade prices are not sourced from all markets
|PE ratio (TTM)||48.07|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|